Despite their remarkable efficacy, anti-TNF-alpha antibodies used as a treatment of inflammatory bowel diseases via systemic administration remain associated with serious adverse effects and mid-term resistance. Thanks to their extreme stability in the gut environment, the Nanofitins allowed the development of orally available anti-TNF-alpha therapeutics. Using these novel protein scaffolds leads to a better targeting to the inflammation site while decreases systemic exposure and related side effects.
Throughout his Ph.D. and postdoctoral researches, Mathieu Cinier acquired extensive training in protein engineering and biotechnology. He has since joined Affilogic, and successfully led 50+ Nanofitin generation programs for a wide range of applications, several of them being currently developed as drug candidates in collaboration with international pharmaceutical partners. He also applied its protein engineering knowledge to expand the potential of the Nanofitin technology, before taking the position of Scientific Director in Jan. 2015.